Perichemotherapy antibiotics improve PDAC survival in patients treated with gemcitabine

Receipt of perichemotherapy antibiotics correlated with improved survival in patients with metastatic pancreatic ductal adenocarcinoma treated with gemcitabine, but not fluorouracil, according to results in JAMA Network Open.“The rapid development of multifactorial resistance to chemotherapy is an important contributor to the dismal prognosis in pancreatic ductal adenocarcinoma (PDAC),” Daniel J. Fulop, BA, of the Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai, and colleagues wrote. “Some preclinical studies have similarlyRead More